AR
Therapeutic Areas
Shattuck Labs Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SL-325 | Inflammatory Bowel Disease (IBD) | Phase 2 |
| SL-425 | Inflammatory Bowel Disease (IBD) | Phase 1 |
| Bispecifics | Autoimmune Diseases | IND-Enabling |
| Drug | Indication | Phase |
|---|---|---|
| SL-325 | Inflammatory Bowel Disease (IBD) | Phase 2 |
| SL-425 | Inflammatory Bowel Disease (IBD) | Phase 1 |
| Bispecifics | Autoimmune Diseases | IND-Enabling |